Skip to main content
. Author manuscript; available in PMC: 2019 Sep 25.
Published in final edited form as: J Immunol. 2009 Feb 1;182(3):1481–1489. doi: 10.4049/jimmunol.182.3.1481

FIGURE 7.

FIGURE 7

Systemic administration of IL-12 to anti-OX40-treated 12-month old mice increased MCA205 tumor-free survival and reduces the accumulation of CD4+CD25+FoxP3+ in the tumors mice treated anti-OX40 and IL-12. Female C57BL/6 mice, two- and 12-months of age, were injected s.c. with 4-5 × 105 MCA205 tumor cells. A. IL-12 (100 ng) or PBS (control) was injected i.p. daily four-to-nine days after tumor challenge. B. Three and seven days after tumor challenge 250 μg anti-OX40 was injected i.p. IL-12 (100 ng) or PBS (control) was injected i.p. daily four-to-nine days after tumor challenge. Mice were then monitored for tumor growth. C. Three and seven days after tumor challenge 250 μg anti-OX40 was injected i.p. IL-12 (100 ng) or PBS (control) was injected i.p. daily four-to-nine days after tumor challenge. Tumors were resected 12 days after tumor challenge and TILs harvested (Materials and Methods). The frequency of CD4+ T cells expressing CD25+ and FoxP3+ from the tumors and pooled contra-lateral lymph nodes from the same mice were assessed by FACs.